Home > Insider Trading > Filing (0001599298-24-000047)

Filing Details

Accession Number:: 0001599298-24-000047
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-03-27 20:28:30
Reporting Period:: 2024-03-26

Accepted Time:: 2024-03-27 20:28:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1599298	Summit Therapeutics Inc.	SMMT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1507650	Mahkam Zanganeh	C/O Summit Therapeutics Inc. 2882 Sand Hill Road, Suite 106 Menlo Park CA 94025	Chief Executive Officer	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-27	26,000	$3.72	520,814	No	4	P	Direct
Common Stock	Acquisiton	2024-03-27	34,321	$3.72	24,923,800	No	4	P	Indirect	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
Common Stock	Acquisiton	2024-03-26	30,000	$3.75	30,000	No	4	P	Indirect	Immediate family member
Common Stock	Acquisiton	2024-03-27	20,000	$3.71	50,000	No	4	P	Indirect	Immediate family member

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Direct
No	4	P	Indirect	By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee
No	4	P	Indirect	Immediate family member
No	4	P	Indirect	Immediate family member

Footnotes

The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.73 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.72 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.73 to $3.78 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.68 to $3.75 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.